scholarly journals A possible interaction between linezolid and digoxin: A case report of therapeutic drug monitoring

2020 ◽  
Vol 28 (11) ◽  
pp. 1408-1410 ◽  
Author(s):  
Zhu Yulin ◽  
Kong Lingti ◽  
Gao Shan ◽  
Zhang Yong
Keyword(s):  
Case Report ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug

scholarly journals Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity

2014 ◽  
Vol 11 (1) ◽  
pp. 25 ◽  
Author(s):  
Yassine Bouatou ◽  
Caroline Samer ◽  
Kuntheavy Ing Lorenzini ◽  
Youssef Daali ◽  
Samira Daou ◽  
...  
Keyword(s):  
Case Report ◽  
Therapeutic Drug Monitoring ◽  
Drug Interactions ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Multiple Drug

Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature

2017 ◽  
Vol 15 (5) ◽  
pp. e885-e887 ◽  
Author(s):  
Pauline Bertolaso ◽  
Marine Gross-Goupil ◽  
Mathieu Molimard ◽  
Valérie Cochin ◽  
Alain Ravaud ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Case Report ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Review Of The Literature

Advantages of everolimus therapeutic drug monitoring in oncology when drug–drug interaction is suspected: A case report

2020 ◽  
Vol 26 (7) ◽  
pp. 1743-1749 ◽  
Author(s):  
Geoffrey Strobbe ◽  
Diane Pannier ◽  
Ilyes Sakji ◽  
Alexandre Villain ◽  
Frédéric Feutry ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Case Report ◽  
Therapeutic Drug Monitoring ◽  
Drug Interactions ◽  
Drug Monitoring ◽  
Plasma Concentrations ◽  
Response To Treatment ◽  
Therapeutic Drug ◽  
High Doses

Introduction Drug interactions involving everolimus are fairly well known because of its common use, primarily as an immunosuppressant. Several recommendations regarding therapeutic drug monitoring are also available for the use of everolimus-based immunosuppression regimens. However, everolimus use in oncology differs substantially, particularly because of the high doses involved. Therapeutic drug monitoring, although sometimes necessary, is not recommended as a routine in oncology. Thus, it was deemed inapplicable due to the lack of clear recommendations. Case report Here, we present a case where a patient was prescribed everolimus for renal cell carcinoma. The patient benefitted from a pharmaceutical consultation prior to treatment initiation, and a drug interaction with verapamil was suspected. Management and outcome: Therapeutic drug monitoring of everolimus was proposed. Based on the everolimus values reported in the literature, trough plasma concentration in the patient was greatly increased. The patient was then diagnosed with grade 4 oral mucositis, thereby requiring temporary suspension of everolimus treatment. Management of adverse effects was performed through multiple medicated mouthwashes. Discussion Therapeutic drug monitoring for everolimus is important for potential drug interactions or the occurrence of severe adverse events. In such cases, dose adjustments should be managed according to everolimus plasma concentrations. Clear oncological recommendations regarding plasma everolimus thresholds are required for a successful follow-up of the patient’s condition and to ensure adequate response to treatment.

Analytical interference during cefepime therapeutic drug monitoring in intensive care patient: About a case report

Therapies ◽  
2017 ◽  
Vol 72 (5) ◽  
pp. 587-592
Author(s):  
Laurie Toullec ◽  
Julien Dupouey ◽  
Coralie Vigne ◽  
Amélie Marsot ◽  
Laurent Allanioux ◽  
...  
Keyword(s):  
Intensive Care ◽  
Case Report ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Intensive Care Patient ◽  
Care Patient ◽  
Therapeutic Drug ◽  
Analytical Interference
Sign in / Sign up

Export Citation Format

Share Document